Literature DB >> 11460208

Human parvovirus B19 infection in HIV-positive patients.

F S Aguiar1, D P Lopes, A R Bazin, S Setúbal, B J Cohen, J P Nascimento.   

Abstract

Parvovirus B19 infects predominantly erythroid cells, leading to transient inhibition of erythropoiesis. Immunocompromised patients may be unable to produce neutralizing antibodies and may develop severe chronic anemia. Epidemiological studies done on Niterói population showed that B19 infection occurs periodically in late spring and summer. We report a study from 55 HIV infected patients attending an infectious diseases outpatient clinic in this city during a 5-month period in which B19 circulation was well documented. All patients were under anti-retroviral therapy. No anti-B19 IgM was found, but a high prevalence of IgG anti-B19 (91%) was observed. In six patients, B19 DNA was found by dot-blot hybridization techniques, but this was not confirmed by PCR. None of these 6 patients manifested anemia and only one had CD4 cell count below 200 x 10(7)/L. We conclude that persistent infection causing anemia is an infrequent finding in our HIV positive patients under drug therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11460208     DOI: 10.1590/s0037-86822001000300002

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

1.  The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa.

Authors:  Chabo Byaene Alain; Lufimbo Katawandja Antoine; Bizeti Nsangu Bizette; Pambu Dahlia; Tshibuela Beya Dophie; Muwonga Masidi Jérémie; Kayembe Nzongola-Nkasu Donatien; Ahuka Mundeke Steve
Journal:  Pan Afr Med J       Date:  2020-03-10

2.  Parvovirus B19 DNA detection in treatment-naïve HIV anemic patients in Lagos, Nigeria: a case control study.

Authors:  Oluwaseyi Sedowhe Ashaka; Olumuyiwa Babalola Salu; Ayorinde Babatunde James; Akeeb Oriowo Bola Oyefolu; AbdulAzeez Adeyemi Anjorin; Bamidele Oludare Oke; Mercy Remilekun Orenolu; Sunday Aremu Omilabu
Journal:  Afr Health Sci       Date:  2020-03       Impact factor: 0.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.